Bai G-H, Park Y-K, Choi Y-W, Bai J-I, Kim H-J, Chang C L, Lee J-K, Kim S J
Korean Institute of Tuberculosis, The Korean National Tuberculosis Association, Seoul, Korea.
Int J Tuberc Lung Dis. 2007 May;11(5):571-6.
The 245 health centres through which the National Tuberculosis Programme (NTP) is implemented in Korea and the TB Laboratory Network of the Korean National Tuberculosis Association.
To observe the trend of anti-tuberculosis drug resistance in Korea from 1994 to 2004 and possible related factors.
All tuberculosis (TB) patients registered for treatment at the health centres for a given period were assessed.
Of 2636 new smear-positive patients from the 2004 survey, 338 cases (12.8%, 95% confidence interval [CI] 11.5-14.1) showed resistance to any of the first-line drugs: 261 with isoniazid (INH) resistance (9.9%, 95%CI 8.8-11.0) and 71 with multidrug resistance (MDR) (2.7%, 95%CI 2.1-3.3). Compared with previous surveys, a statistically significant increase in MDR (P=0.00675), any drug resistance (P=0.03779), any INH resistance (P=0.00313) and any rifampicin resistance (P = 0.00176) has been observed among new cases since 1994. Any resistance to second-line drugs ranged from 0.1% (capreomycin) to 1.1% (para-aminosalicylic acid) among new cases and from 1.1% to 3.6% among retreatment cases. Resistance to kanamycin and ofloxacin was found in 1.4% and 2.6%, respectively, of new and previously treated MDR-TB cases.
A statistically significant increase in drug resistance was noticed among new cases.
韩国通过245家保健中心实施国家结核病防治规划（NTP），以及韩国全国结核病协会的结核病实验室网络。
观察1994年至2004年韩国抗结核药物耐药性的变化趋势及可能的相关因素。
对在特定时期内在保健中心登记接受治疗的所有肺结核（TB）患者进行评估。
在2004年调查的2636例新涂片阳性患者中，338例（12.8%，95%置信区间[CI]11.5 - 14.1）对任何一种一线药物耐药：261例对异烟肼（INH）耐药（9.9%，95%CI 8.8 - 11.0），71例对多种药物耐药（MDR）（2.7%，95%CI 2.1 - 3.3）。与以往调查相比，自1994年以来，新病例中MDR（P = 0.00675）、任何药物耐药（P = 0.03779）、任何INH耐药（P = 0.00313）和任何利福平耐药（P = 0.00176）均有统计学显著增加。新病例中对二线药物的任何耐药率在0.1%（卷曲霉素）至1.1%（对氨基水杨酸）之间，复治病例中在1.1%至3.6%之间。在新的和既往治疗的耐多药结核病病例中，分别有1.4%和2.6%对卡那霉素和氧氟沙星耐药。
新病例中耐药性有统计学显著增加。
